Oncocyte_Logo_Horizontal_Main.jpg
Medicare Coverage Determination for Molecular Testing Announced for Solid Organ Allograft Rejection, Citing Multiple Publications from OncoCyte Corporation’s Subsidiary Chronix Biomedical, Inc.
May 06, 2021 08:00 ET | Oncocyte Corporation
Coverage policy for transplant rejection monitoring establishes a simplified and accelerated pathway for Medicare coverage of Chronix’s solid organ transplant rejection monitoring test Oncocyte’s...
Oncocyte_Logo_Horizontal_Main.jpg
Oncocyte to Report First Quarter 2021 Financial Results on Monday, May 17
May 04, 2021 16:01 ET | Oncocyte Corporation
IRVINE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...
Oncocyte_Logo_Horizontal_Main.jpg
Oncocyte to Present New Data on DetermaIO™ Test as a Predictor of Immunotherapy Response in Renal Cell Cancer at the 2021 ASCO Annual Meeting
April 28, 2021 16:31 ET | Oncocyte Corporation
IRVINE, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...
Oncocyte_Logo_Horizontal_Main.jpg
Oncocyte Enters the Rapidly Growing Immune Therapy Monitoring Market with the Closing of the Acquisition of Chronix Biomedical, Inc.
April 19, 2021 08:00 ET | Oncocyte Corporation
Oncocyte gains proprietary capabilities for immune therapy monitoring and transplant rejection testing, both from a standard blood sample Oncocyte’s technologies may provide more precision to the...
Oncocyte_Logo_Horizontal_Main.jpg
Oncocyte Hosting Key Opinion Leader Call on Novel Biomarkers in Identifying Appropriate Responders to Immune Checkpoint Inhibitors
April 14, 2021 09:02 ET | Oncocyte Corporation
IRVINE, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...
Oncocyte_Logo_Horizontal_Main.jpg
Oncocyte Presents New Data at 2021 American Association for Cancer Research Annual Meeting Demonstrating Potential for Pan-Cancer Utility of DetermaIO™
April 10, 2021 13:31 ET | Oncocyte Corporation
Achieved primary endpoint demonstrating significant correlation between DetermaIO and two-year overall survival rate to atezolizumab in metastatic bladder cancer DetermaIO identified additional...
Oncocyte_Logo_Horizontal_Main.jpg
Oncocyte to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare Conference
April 06, 2021 16:05 ET | Oncocyte Corporation
IRVINE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...
Oncocyte_Logo_Horizontal_Main.jpg
Oncocyte Provides Corporate Update and Reports Fourth Quarter and Annual 2020 Financial Results
March 16, 2021 16:01 ET | Oncocyte Corporation
DetermaRx commercialization momentum continues with 36% sample growth and 58% revenue growth compared to Q3 2020 On track to launch DetermaIO™ in 2021 for immune therapy selection ...
Oncocyte_Logo_Horizontal_Main.jpg
Oncocyte Announces Peer-Reviewed Publication of Data Assessing Use of DetermaIO™ to Identify Patients Likely to Benefit from Immunotherapy Across Multiple Tumor Types
March 16, 2021 08:00 ET | Oncocyte Corporation
Novel immuno-oncology algorithm may offer independent and incremental predictive value over current standard biomarkers in the clinic Data suggest that measuring the tumor microenvironment (TME) as a...
Oncocyte_Logo_Horizontal_Main.jpg
Oncocyte To Present New Data at 2021 American Association for Cancer Research (AACR) Annual Meeting Demonstrating Potential for Pan-Cancer Utility of DetermaIO™
March 15, 2021 08:00 ET | Oncocyte Corporation
-Results achieved in metastatic bladder cancer suggests Oncocyte’s DetermaIO test may be a strong predictor of Immune Checkpoint Inhibitor (ICI) therapy response in a third cancer type in addition to...